Bong originally joined Venrock in 2009 and has been doing public and private investing since 2004. He did his medical training at Harvard’s Mass Eye & Ear Infirmary (ophthalmology), Stanford Hospital (internal medicine) and UCSF (pathology).
Bong is a manager of Venrock’s public and cross-over biotech fund, Venrock Healthcare Capital Partners, where he provides leadership in biotech investments.
On the private side, Bong led Venrock’s investments in Aeglea Biotherapeutics, Akari Therapeutics (PIPE), Avalanche Biotechnologies (series B), Audentes Therapeutics (series B), AveXis (pre-mezzanine and series D), Juno Therapeutics (series A), KalVista Pharmaceuticals, REGENXBIO (series C & D) and Replicor (first institutional investor round).
Bong is on the AveXis’ board of directors and is an observer at REGENXBIO Inc., KalVista Pharmaceuticals and Audentes Therapeutics.
Bong earned his B.A. from Yale University, his M.D. from the University of California, San Francisco, and an M.B.A. from Harvard Business School.